ANDROMEDA Study Results Presented at ADA's Annual Meeting

Supplements and Featured Publications, Practical Lipid Management - Exciting New Advances in Lipid Management, Volume 10, Issue 1 Pract

ORLANDO—The results of the ANDROMEDA Study were presented at the 64th Scientific Sessions of the American Diabetes Association. The study demonstrated that rosuvastatin at the lowest dose (10 mg) provides greater reduction in levels of non—high-density lipoprotein (non-HDL) cholesterol in patients with type 2 diabetes compared with atorvastatin (10 mg).

The study consisted of 509 adult patients who were randomized to receive rosuvastatin 10 mg or atorvastatin 10 mg for 8 weeks. Doses were then increased to 20 mg for an additional 8 weeks. The baseline non-HDL cholesterol levels in the rosuvastatin and atorvastatin groups were 4.30 ± 1.0 mmol/L and 4.33 ± 1.0 mmol/L. Baseline triglyceride (TG) levels in the rosuvastatin and atorvastatin groups were 2.04 ± 1.0 mmol/L and 2.12 ± 1.0 mmol/L, respectively.

Rosuvastatin at both doses, 10 mg and 20 mg, significantly reduced the non-HDL cholesterol and TG levels of patients compared with atorvastatin (Table).